85 related articles for article (PubMed ID: 26795083)
1. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
Pinnix CC; Shah JJ; Chuang H; Costelloe CM; Medeiros LJ; Wogan CF; Reed V; Smith GL; Milgrom S; Patel K; Huo J; Turturro F; Romaguera J; Fayad L; Oki Y; Fanale MA; Westin J; Nastoupil L; Hagemeister FB; Rodriguez A; Qazilbash M; Shah N; Bashir Q; Ahmed S; Nieto Y; Hosing C; Rohren E; Dabaja B
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):122-8. PubMed ID: 26795083
[TBL] [Abstract][Full Text] [Related]
2. Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.
Arora N; Gupta A; Sadeghi N
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28993364
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
Hess BT; Giri A; Park Y; Patel KK; Link BK; Nowakowski GS; Maliske SM; Fortin S; Chavez JC; Saeed H; Hill BT; Mejia Garcia AV; Maddocks KJ; Hanel W; Wagner-Johnston ND; Messmer MR; Kahl BS; Watkins M; Alderuccio JP; Lossos IS; Nathan S; Orellana-Noia VM; Portell CA; Landsburg DJ; Ayers EC; Castillo JJ
Am J Hematol; 2023 Feb; 98(2):300-308. PubMed ID: 36588409
[TBL] [Abstract][Full Text] [Related]
4. Orbital plasmablastic lymphoma with remission following chemotherapy.
Degnan AJ; Levy LM
J Radiol Case Rep; 2011; 5(2):1-7. PubMed ID: 22470775
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features and abnormal signaling pathways in plasmablastic lymphoma: a multicenter study in China.
Shi D; Gao L; Wan XC; Li J; Tian T; Hu J; Zhang QL; Su YF; Zeng YP; Hu ZJ; Yu BH; Li XQ; Wei P; Li JW; Zhou XY
BMC Med; 2022 Dec; 20(1):483. PubMed ID: 36522654
[TBL] [Abstract][Full Text] [Related]
6. Duodenal plasmablastic lymphoma in an human immunodeficency virus-negative patient: a case report.
Hussain AA; Shah AM; Kumar S
J Med Case Rep; 2023 Oct; 17(1):414. PubMed ID: 37777745
[TBL] [Abstract][Full Text] [Related]
7. Plasmablastic lymphoma: from genetics to treatment.
Frontzek F; Hailfinger S; Lenz G
Leuk Lymphoma; 2023 Apr; 64(4):799-807. PubMed ID: 36577021
[TBL] [Abstract][Full Text] [Related]
8. Transformed Plasmablastic Lymphoma Presenting With Marked Lymphocytosis and Spontaneous Tumor Lysis Syndrome.
Hadjiyannis Y; Miller C; Hollie NI; Balakrishna J; Cottini F
J Hematol; 2023 Feb; 12(1):49-58. PubMed ID: 36895289
[TBL] [Abstract][Full Text] [Related]
9. Plasmablastic Lymphoma: Past, Present, and Future.
Kaur S; Kollimuttathuillam S
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e253-e259. PubMed ID: 37453866
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma.
Ryu YK; Ricker EC; Soderquist CR; Francescone MA; Lipsky AH; Amengual JE
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013165
[TBL] [Abstract][Full Text] [Related]
11. Recurrent PET FDG Uptake after Sequential Chemotherapy and Radiation Therapy for DLBCL of the Tibia: A Case Report and Review of the Literature.
Miles EF; Balsamo L; Turton DB; Graf W
Case Rep Oncol Med; 2011; 2011():163472. PubMed ID: 22606440
[TBL] [Abstract][Full Text] [Related]
12. An in vitro demonstration of overcoming drug resistance in SKOV3 TR and MCF7 ADR with targeted delivery of polymer pro-drug conjugates.
Bhattarai P; Vance D; Hatefi A; Khaw BA
J Drug Target; 2017 Jun; 25(5):436-450. PubMed ID: 27937085
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.
Cheah CY; Chihara D; Ahmed M; Davis RE; Nastoupil LJ; Phansalkar K; Hagemeister FB; Fayad LE; Westin JR; Oki Y; Fanale MA; Romaguera JE; Wang ML; Lee H; Turturro F; Samaniego F; Rodriguez MA; Neelapu SS; Fowler NH
Ann Oncol; 2016 May; 27(5):895-901. PubMed ID: 26802151
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Möricke A; Zimmermann M; Valsecchi MG; Stanulla M; Biondi A; Mann G; Locatelli F; Cazzaniga G; Niggli F; Aricò M; Bartram CR; Attarbaschi A; Silvestri D; Beier R; Basso G; Ratei R; Kulozik AE; Lo Nigro L; Kremens B; Greiner J; Parasole R; Harbott J; Caruso R; von Stackelberg A; Barisone E; Rössig C; Conter V; Schrappe M
Blood; 2016 Apr; 127(17):2101-12. PubMed ID: 26888258
[TBL] [Abstract][Full Text] [Related]
15. Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.
Illidge TM; McKenzie HS; Mayes S; Bates A; Davies AJ; Pettengell R; Stanton L; Cozens K; Hampson G; Dive C; Zivanovic M; Tipping J; Gallop-Evans E; Radford JA; Johnson PW
Br J Haematol; 2016 Apr; 173(2):274-82. PubMed ID: 26849853
[TBL] [Abstract][Full Text] [Related]
16. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group.
Tchernonog E; Faurie P; Coppo P; Monjanel H; Bonnet A; Algarte Génin M; Mercier M; Dupuis J; Bijou F; Herbaux C; Delmer A; Fabiani B; Besson C; Le Gouill S; Gyan E; Laurent C; Ghesquieres H; Cartron G
Ann Oncol; 2017 Apr; 28(4):843-848. PubMed ID: 28031174
[TBL] [Abstract][Full Text] [Related]
18. Plasmablastic lymphoma: current perspectives.
Lopez A; Abrisqueta P
Blood Lymphat Cancer; 2018; 8():63-70. PubMed ID: 31360094
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological analysis of oral plasmablastic lymphoma: A systematic review.
Rodrigues-Fernandes CI; de Souza LL; Santos-Costa SFD; Silva AMB; Pontes HAR; Lopes MA; de Almeida OP; Brennan PA; Fonseca FP
J Oral Pathol Med; 2018 Nov; 47(10):915-922. PubMed ID: 29917262
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
